Methotrexat Accord (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, preventing the formation of tetrahydrofolate, a key cofactor for synthesising purine nucleotides and thymidylate. This inhibition disrupts DNA, RNA, and protein production, limiting the proliferation of rapidly dividing cancer cells and dampening the activity of immune cells involved in inflammation.

The specific dose of Methotrexat Accord is determined by the prescribing physician based on the patient’s diagnosis, disease severity, renal and hepatic function, and treatment protocol. Dosage regimens can vary widely, and the prescriber will tailor the amount and frequency to achieve optimal therapeutic effect while minimizing toxicity.

Methotrexate is classified as contraindicated in pregnancy because it can cause fetal malformations and miscarriage. Women of child‑bearing potential should use effective contraception before, during, and after treatment. Breastfeeding is also discouraged, as methotrexate can be excreted in milk and may harm the infant.

To place an order, visit the product page on gnhindia.com, submit an enquiry with the required quantity, and provide your institutional or trade credentials. GNH India works with hospitals, pharmacies, and procurement teams worldwide, responding with pricing, availability, shipping details—including cold‑chain handling if needed—and any necessary import documentation.

Methotrexat Accord, as a folate antagonist, differs from agents such as anthracyclines or taxanes that target microtubules or DNA intercalation. Its mechanism focuses on inhibiting nucleotide synthesis, offering a distinct toxicity profile and allowing combination with other chemotherapy classes. Choice of therapy depends on cancer type, stage, and patient tolerance.

Methotrexat Accord should be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. Maintaining the cold chain preserves drug stability and potency until administration.

Methotrexat Accord is supplied as a sterile injectable solution and can be given via intra‑arterial, intramuscular, or intravenous routes, depending on the clinical indication and treatment protocol. Administration is performed by qualified healthcare professionals in a controlled setting, often with pre‑ and post‑hydration measures to reduce toxicity.

The most serious risks include myelosuppression leading to severe infections, hepatic toxicity that can progress to fibrosis or cirrhosis, pulmonary toxicity such as interstitial pneumonitis, and renal impairment that may exacerbate drug accumulation. Prompt monitoring of blood counts, liver and kidney function is essential to detect these complications early.

Methotrexat Accord is contraindicated in patients with severe renal or hepatic impairment, uncontrolled infections, known hypersensitivity to methotrexate or its excipients, and in pregnant or breastfeeding women. Caution is also advised for individuals with compromised immune systems or those receiving live vaccines.